CDC42 and neoplasm: Silencing Cdc42 with siRNA has been shown in vitro to reprogram pericytes, changing their phenotype from a tumor-promoting, angiogenic state to a tumor-suppressive one, resembling pro-inflammatory M1 macrophages.